SV

Street Verdict

Analyst Scorecard

AUROPHARMA · NSE

Aurobindo Pharma Limited

₹1,799

-0.37% (-₹6.7)

Prev. close

₹1,805.7

Volume

8,11,247

Delivery %

61.6%

As of

20 Nov 2026

Price history

₹1,799+₹154 (+9.36%) · 3M
18 Aug 2026 → 20 Nov 2026
1,6001,6501,7001,7501,8001,85018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

5 analyst stances · last 90 days · one per analyst

Trackable

5 · 5 bull / 0 neutral / 0 bear

Long-Horizon

none in range

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (5)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 3 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Aurobindo Pharma Limited

Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides ointments, creams, gels, powders, transdermal, and lotions; antiretroviral drugs for PLHIV & CLHIV; and injectable products, including Penems, Penicillin, Cephalosporin, ophthalmic, inhalation, oncology, and hormone products. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Dr. Makkapati Satakarni B.E., M.B.A., Ph.D.

Headquarters

Hyderabad

Employees

29,209

Key stats

Market cap

₹98,101.93 Cr

P/E ratio (TTM)

26.6

Dividend yield

0.00%

EPS (TTM)

₹64.00

Beta (1Y · daily vs NIFTY 50)

0.39

Beta (5Y · monthly vs NIFTY 50)

0.89

Shares float

27.61 Cr

EPS · quarter ended Jun 2026

₹17.86

Financial Performance

01 · Financials

0 Cr10000 Cr20000 Cr30000 Cr40000 Cr₹0%10%20%30%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

0255075100₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

0246₹-100%-50%0%50%100%17 Feb 2021 Aug 2023 Nov 2022 Feb 2127 Aug 2117 Nov 2118 Feb 2206 Jun 2217 Feb 2320 Nov 2320 Feb 2408 Aug 25
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-20%0%20%40%FY21FY22FY23FY24FY25FY26
SalesFixed assetsReceivables (trade + unbilled)Inventory

05 · Capital Structure & Asset Utilization

0 Cr20000 Cr40000 Cr60000 Cr₹0×0.2×0.4×0.6×0.8×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr20000 Cr40000 Cr60000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-5000 Cr0 Cr5000 Cr10000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

Total assets for FY23, FY24, FY25 and FY26: the figure the company printed, which its own totals confirm and the series' figure did not.

08 · Profit & Loss — as filed

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹25,155.47 Cr₹23,775.84 Cr₹25,145.97 Cr₹29,559.25 Cr₹32,345.58 Cr₹34,145.17 Cr
₹20,571.10 Cr₹20,243.88 Cr₹22,521.80 Cr₹24,970.24 Cr₹27,247.60 Cr₹28,969.51 Cr
PROFIT BEFORE SHARE OF (LOSS)/PROFIT OF JOINT VENTURES
₹4,584.37 Cr₹3,531.96 Cr₹2,624.17 Cr₹4,589.01 Cr₹5,097.98 Cr₹5,175.66 Cr
Share of Profit/ (loss) of associates and joint ventures (net of tax)
₹-55.36 Cr₹-31.25 Cr₹-11.67 Cr₹-17.16 Cr₹-31.69 Cr₹1.52 Cr
PROFIT BEFORE EXCEPTIONAL ITEMS AND TAX (III+IV)
₹4,529.01 Cr₹3,500.71 Cr₹2,612.50 Cr₹4,571.85 Cr₹5,066.29 Cr₹5,177.18 Cr
Exceptional items
₹-2,814.58 Cr₹127.97 Cr—₹191.86 Cr—₹65.33 Cr
PROFIT BEFORETAX (V-VI)
₹7,343.59 Cr₹3,372.74 Cr₹2,612.50 Cr₹4,379.99 Cr₹5,066.29 Cr₹5,111.85 Cr
₹2,009.77 Cr₹725.63 Cr₹684.85 Cr₹1,211.02 Cr——
TOTALTAX EXPENSE (VIII)
————₹1,582.72 Cr₹1,608.88 Cr
₹5,338.56 Cr₹2,908.76 Cr₹2,663.23 Cr₹3,268.13 Cr₹3,787.19 Cr₹5,468.17 Cr
PROFIT FOR THE YEAR (VII-VIII)
₹5,333.82 Cr₹2,647.11 Cr₹1,927.65 Cr₹3,168.97 Cr₹3,483.57 Cr₹3,502.97 Cr
₹4.74 Cr₹261.65 Cr₹735.58 Cr₹99.16 Cr₹303.62 Cr₹1,965.20 Cr
Owners of the Parent Company
₹5,339.58 Cr₹2,909.80 Cr₹2,663.08 Cr₹3,272.13 Cr₹3,789.51 Cr₹5,469.94 Cr
Non-controlling interest
₹-1.02 Cr₹-1.04 Cr₹15.00 L₹-4.00 Cr₹-2.32 Cr₹-1.77 Cr
Owners of the Parent Company
₹5,334.84 Cr₹2,648.15 Cr₹1,927.50 Cr₹3,172.97 Cr₹3,485.88 Cr₹3,504.75 Cr
Non-controlling interest
₹-1.02 Cr₹-1.04 Cr₹15.00 L₹-4.00 Cr₹-2.31 Cr₹-1.78 Cr
Owners of the Parent Company
₹4.74 Cr₹261.65 Cr₹735.58 Cr₹99.16 Cr₹303.63 Cr₹1,965.19 Cr
Non-controlling interest
————₹-1.00 L₹1.00 L
(ii) Diluted (in ₹)
91.0545.19————
Nominal value per equity share
1.001.00————
Basic and diluted (in)
91.0545.1932.9054.1659.8160.34

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

09 · Balance Sheet — as filed

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹33,853.99 Cr₹33,921.72 Cr₹39,889.99 Cr₹45,071.51 Cr₹49,784.97 Cr₹58,502.15 Cr
(i) Borrowings
₹168.49 Cr—————
(ii) Lease liabilities
₹266.19 Cr—————
(b) Provisions
₹157.11 Cr—————
(i) Borrowings
₹4,803.78 Cr—————
(iii) Lease liabilities
₹100.62 Cr—————
(iv) Other financial liabilities
₹2,027.50 Cr—————
(c) Provisions
₹171.93 Cr—————
₹21,928.99 Cr—————
₹21,928.99 Cr₹24,574.05 Cr₹26,851.85 Cr₹29,850.80 Cr₹32,646.93 Cr₹37,882.81 Cr
₹1,259.95 Cr—————
Total non-current liabilities
₹1,259.95 Cr₹1,191.69 Cr₹1,544.36 Cr₹3,021.58 Cr₹2,455.70 Cr₹2,580.33 Cr
₹10,665.05 Cr—————
₹33,853.99 Cr—————
TOTAL EQUITY AND LIABILITIES
₹33,853.99 Cr₹33,921.72 Cr₹39,889.99 Cr₹45,071.51 Cr₹49,784.97 Cr₹58,502.15 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

† Computed, not printed: that year’s report leaves this figure out, but the lines it does print fix it exactly (hover for the sum). The same relationship holds in every year where all of its lines are printed.

All years: consolidated statements.

10 · Cash Flow Statement — as filed

Annual

Line itemFY21FY22FY23FY24FY25
₹2,562.80 Cr₹-1,164.35 Cr₹223.41 Cr₹-1,021.01 Cr₹2,168.60 Cr
₹3,329.05 Cr₹5,016.48 Cr₹2,386.75 Cr₹2,434.52 Cr₹3,924.62 Cr
₹598.69 Cr₹-3,211.56 Cr₹-3,977.75 Cr₹-4,255.95 Cr₹-1,875.80 Cr
₹-1,364.94 Cr₹-2,969.27 Cr₹1,814.41 Cr₹800.42 Cr₹119.78 Cr
Cash and cash equivalents at the beginning of the year
₹2,746.82 Cr₹5,329.91 Cr₹4,162.51 Cr₹4,392.27 Cr₹3,385.43 Cr
Add: Cash and cash equivalents on acquisition of subsidiaries (refer note 38)
₹22.41 Cr₹-3.25 Cr₹6.41 Cr—₹66.00 L
Effect of exchange differences on cash and cash equivalents
₹-2.12 Cr₹20.00 L₹-6.00 L₹14.17 Cr₹9.10 Cr
Cash and cash equivalents at the end of the year
₹5,329.91 Cr₹4,162.51 Cr₹4,392.27 Cr₹3,385.43 Cr₹5,563.79 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21–Mar 24(11Q)Jun 24Sep 24–Mar 26(7Q)Jun 26
Promoter51.83%51.80%51.82%51.88%
Public48.17%48.20%48.18%48.12%
Employee trusts0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Lupin Limited₹92,244.53 Cr₹2,008.616.74.1123.8%0.29+23.9%+0.6%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

AUROPHARMA

Aurobindo Pharma stock: Q2 profit rises 32.5% on record revenue

ad-hoc-news.de · 10 days ago

AUROPHARMA

Aurobindo Pharma Submits Q2 FY27 Earnings Call Transcript

TipRanks · 11 days ago